Eisai And Biogen's Lecanemab: A Flawed Treatment For Alzheimer's Disease

Summary

• Lecanemab only significantly slows down the progression of Alzheimer's disease in APOE4 carriers.
• Lecanemab is suspected of causing at least three deaths.
• The FDA may still grant approval to lecanemab with a warning label regarding brain bleeds and brain swelling.
• Medicare may deny coverage of lecanemab outside of any further clinical trials based on cost, safety, and efficacy concerns.
• The likelihood of long-term down side pressure on Biogen Inc. and Eisai's stock value seems more likely than long-term positive movement.

DNY59/iStock via Getty Images

The Food and Drug Administration (FDA) will soon be considering whether to approve lecanemab for Alzheimer’s disease. If the FDA grants accelerated approval to the drug, Medicare may still not cover lecanemab due to cost, safety, and efficacy concerns. In addition better

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.